Inherited CD59 deficiency, where neurology and genetics intertwine.

IF 1.2 4区 医学 Q4 CLINICAL NEUROLOGY Neurosciences Pub Date : 2023-04-01 DOI:10.17712/nsj.2023.2.20220119
Lateefa M Almutawea, Amani A Al Hajeri, Eman M Farid, Maryam Y Bushail, Ayman K Ali
{"title":"Inherited CD59 deficiency, where neurology and genetics intertwine.","authors":"Lateefa M Almutawea,&nbsp;Amani A Al Hajeri,&nbsp;Eman M Farid,&nbsp;Maryam Y Bushail,&nbsp;Ayman K Ali","doi":"10.17712/nsj.2023.2.20220119","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To describe the clinical phenotype of eight children diagnosed with CD59 deficiency and their ultimate neurological outcome.</p><p><strong>Methods: </strong>The data of our cases were extensively reviewed both clinical and ancillary tests; investigations included: neuroimaging, neurophysiological studies, and laboratory tests.</p><p><strong>Results: </strong>All patients presented during early infancy with Guillain-Barre syndrome later they suffered repeated relapses leading to the diagnosis of chronic axonal neuropathy. Recurrent stroke and acute necrotizing encephalopathy were described, 2 patients in each group. One girl developed acute disseminated encephalomyelitis while one boy developed acute transverse myelitis. Overt hemolytic anemia requiring blood transfusion reported in six patients.</p><p><strong>Conclusion: </strong>Inherited CD59 deficiency is an autosomal recessive disorder which can have devastating neurological consequences. First line immunotherapy including intravenous immunoglobin, corticosteroids, and plasma exchange may have transient beneficial effect. Reports of targeted therapy with eculizumab might be lifesaving. Genetic counseling is crucial.</p>","PeriodicalId":19284,"journal":{"name":"Neurosciences","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/18/67/Neurosciences-28-2-130.PMC10155482.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurosciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.17712/nsj.2023.2.20220119","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: To describe the clinical phenotype of eight children diagnosed with CD59 deficiency and their ultimate neurological outcome.

Methods: The data of our cases were extensively reviewed both clinical and ancillary tests; investigations included: neuroimaging, neurophysiological studies, and laboratory tests.

Results: All patients presented during early infancy with Guillain-Barre syndrome later they suffered repeated relapses leading to the diagnosis of chronic axonal neuropathy. Recurrent stroke and acute necrotizing encephalopathy were described, 2 patients in each group. One girl developed acute disseminated encephalomyelitis while one boy developed acute transverse myelitis. Overt hemolytic anemia requiring blood transfusion reported in six patients.

Conclusion: Inherited CD59 deficiency is an autosomal recessive disorder which can have devastating neurological consequences. First line immunotherapy including intravenous immunoglobin, corticosteroids, and plasma exchange may have transient beneficial effect. Reports of targeted therapy with eculizumab might be lifesaving. Genetic counseling is crucial.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
遗传性CD59缺陷,神经学和遗传学交织在一起。
目的:描述8例被诊断为CD59缺乏症的儿童的临床表型及其最终的神经预后。方法:广泛回顾我们病例的临床和辅助测试数据;调查包括:神经影像学、神经生理学研究和实验室检查。结果:所有患者均在婴儿期早期出现格林-巴利综合征,后来反复复发,最终诊断为慢性轴索神经病变。复发性脑卒中和急性坏死性脑病,每组2例。一名女孩发展为急性播散性脑脊髓炎,一名男孩发展为急性横断面脊髓炎。6例患者报告了明显的溶血性贫血需要输血。结论:遗传性CD59缺乏症是一种常染色体隐性遗传病,可造成严重的神经系统后果。一线免疫治疗包括静脉注射免疫球蛋白、皮质类固醇和血浆置换可能有短暂的有益效果。eculizumab靶向治疗的报道可能会挽救生命。遗传咨询至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Neurosciences
Neurosciences 医学-临床神经学
CiteScore
1.40
自引率
0.00%
发文量
54
审稿时长
4.5 months
期刊介绍: Neurosciences is an open access, peer-reviewed, quarterly publication. Authors are invited to submit for publication articles reporting original work related to the nervous system, e.g., neurology, neurophysiology, neuroradiology, neurosurgery, neurorehabilitation, neurooncology, neuropsychiatry, and neurogenetics, etc. Basic research withclear clinical implications will also be considered. Review articles of current interest and high standard are welcomed for consideration. Prospective workshould not be backdated. There are also sections for Case Reports, Brief Communication, Correspondence, and medical news items. To promote continuous education, training, and learning, we include Clinical Images and MCQ’s. Highlights of international and regional meetings of interest, and specialized supplements will also be considered. All submissions must conform to the Uniform Requirements.
期刊最新文献
Assessment of clinician adherence to Fingolimod instructions and its effect on patient safety. Can artificial intelligence techniques help clinicians assess and treat patients with bone fractures? CAN PROBIOTICS PLUS VITAMIN D SUPPLEMENTS BENEFIT PEOPLE WITH SCHIZOPHRENIA? Comment on: Effectiveness of radiology modalities in diagnosing and characterizing brain disorders. Intracerebral benign fibrous histiocytoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1